Nchemotherapy induced thrombocytopenia pdf merger

Thrombocytopenia is a common problem in patients with cancer. Dova is also conducting a phase 3 trial in chemotherapy induced thrombocytopenia cit which is a common side effect of chemotherapy that results in a low number of platelets. Immune thrombocytopenia itp is an autoimmune bleeding disorder with. Although there are several different causes for thrombocytopenia, including deficiency in platelet production, excessive platelet destruction, and sequestration of platelets in the spleen, the predominant reason for a low platelet count in cancer patients receiving chemotherapy is a deficiency in platelet production. Itp is a rare autoimmune bleeding disorder characterised by a low number of platelets. Chemotherapy dose reduction and platelet transfusions remain the major treatments for affected patients.

Existing guidelines describe the management and treatment of most patients who, overall, do well. Chemotherapyinduced thrombocytopenia cit can complicate surgical procedures and can lead to chemotherapy dose delays, dose reductions, or discontinuation, which may result in suboptimal patient outcomes, and cit increases the likelihood of serious bleeding events, which may result in hospitalization 2,3,4,5,6,7. Management of chemotherapyinduced thrombocytopenia. Dova pharmaceuticals to be acquired by swedish orphan. At platelet counts chemotherapyinduced thrombocytopenia, given the increased risk of secondary myelodysplastic syndrome mds and acute myeloid leukemia aml associated with use of chemotherapy, are that chronic use of exogenous thrombopoietic agents could promote the development of these diseases. Chronic immune thrombocytopenia itp indication is expected in 2020. Purposechemotherapyinduced thrombocytopenia cit leads to delay or reduction in cancer treatment. Thrombocytopenia is a common problem in cancer patients. Thrombocytopenia, an abnormally low blood platelet count, is a potentially serious and costly complication of myelosuppressive chemotherapy 1, 2. Risk and consequences of chemotherapyinduced thrombocytopenia in us clinical practice. Platelet transfusion guidelines are based on excellent evidence,5 but this. Romiplostim treatment of chemotherapyinduced thrombocytopenia. Yerevan state medical university, muratsan hospital complex, clinic of chemotherapy, yerevan, armenia. Thrombocytopenia creates a number of problems in the care of a cancer patient.

In evaluating thrombocytopenic cancer patients, it is important to assess for other causes of thrombocytopenia, including immune thrombocytopenia, coagulopathy, infection, drug reaction, posttransfusion purpura, and thrombotic microangiopathy. Aside from bleeding risk, thrombocytopenia limits chemotherapy dose and frequency. Introduction thrombocytopenia is a common problem in patients with cancer. Although few studies have been completed to demonstrate their ability to treat chemotherapyinduced thrombocytopenia, these agents may be useful in treating this condition in some situations. Pdf prophylactic platelet transfusion for prevention of bleeding in. It can result from chemotherapy or radiation treatment, or from the underlying disease itself. Chemotherapyinduced thrombocytopenia practiceupdate. In evaluating thrombocytopenic cancer patients, it is important to assess for. Pdf managing thrombocytopenia associated with cancer. Fda grants avatrombopag orphan drug designation for the.